Key Takeaways Novo Nordisk's U.S.-listed shares tumbled over 19% Friday morning after it released data from a new weight loss ...

Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently ...

Shares in Danish pharmaceutical giant Novo Nordisk, maker of diabetes and weight-loss treatments Ozempic and Wegovy, plunged ...

Shares in the company dived after a new anti-obesity treatment missed expectations in a study, denting its chances of ...